Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
Kimberly-Clark Corp.
KMBConsumer StaplesGenerated Jul 5, 2026, 08:13 PM UTC
KMB (Kimberly-Clark Corp.) analytical snapshot. Revenue declined +15.0% YoY to $17.15B. Net margin at 10.29% (contracting ▼). Return on equity 210.00%, ROA 10.66%, ROIC 229.52%. Market cap $38.08B at $114.72 per share. Trailing P/E 22.02, P/S 2.22, P/B 21.20. EV/Operating income ≈ 23.31 (EV $44.94B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -10 (data confidence 82%). Descriptive analytics from public filings — not investment advice.
Market cap
$38.08B
331.94M shares
Price
$114.72
NMS
P/E (ttm)
22.02
Revenue (FY)
$17.15B
YoY -15.0%
Net margin
10.29%
▼ 2.00pp
Free cash flow
$2.78B
16.19% margin
Risk level
Elevated
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score -70Deteriorating
80% conf
Revenue declined +15.0% YoY to $17.15B. Net margin at 10.29% (contracting ▼). Return on equity 210.00%, ROA 10.66%, ROIC 229.52%.
- Revenue declined +15.0% YoY to $17.15B.
- Net margin at 10.29% (contracting ▼).
- Return on equity 210.00%, ROA 10.66%, ROIC 229.52%.
- Gross margin 36.56%, operating margin 11.24%.
- Free cash flow margin 16.19% ($2.78B).
- Net income down ▼ +8.8% YoY.
- Debt/equity 4.12, current ratio 0.77, net debt $6.86B.
- Asset turnover 1.00 — capital efficiency.
Revenue (FY)
$17.15B
YoY -15.0%
Net margin
10.29%
▼ 2.00pp
ROE
210.00%
ROA 10.66%
ROIC
229.52%
EPS (diluted)
$5.21
FY2025
Free cash flow
$2.78B
16.19% margin
Debt / equity
4.12
Cash $542.0M
Current ratio
0.77
Equity $1.80B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | — | — | — | — | — | — | -877.01 |
| 2017 | — | — | — | — | — | $1.25B | -993.14 |
| 2018 | — | — | — | — | — | $2.46B | 344.36 |
| 2019 | $18.35B | — | 35.90 | 18.30 | 12.42 | $2.14B | -793.73 |
| 2020 | $18.49B | +0.8% | 30.28 | 12.06 | 7.63 | $2.09B | -4272.73 |
| 2021 | $18.45B | -0.2% | 32.71 | 16.21 | 11.69 | $1.53B | 344.57 |
| 2022 | $19.14B | +3.7% | 35.64 | 16.95 | 12.29 | $2.51B | 457.59 |
| 2023 | $19.44B | +1.6% | 30.80 | 13.17 | 9.33 | $1.72B | 331.63 |
| 2024 | $20.18B | +3.8% | 30.83 | 13.29 | 9.59 | $1.86B | 211.37 |
| 2025 | $17.15B | -15.0% | 36.56 | 11.24 | 10.29 | $2.78B | 210.00 |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 31, 2025 | $4.05B | -21.3% | — | 13.99% |
| Jun 30, 2025 | $8.22B | -19.3% | +102.7% | 13.09% |
| Jun 30, 2025 | $4.16B | -59.1% | -49.3% | 25.85% |
| Sep 30, 2025 | $12.37B | -18.3% | +197.1% | 12.31% |
| Sep 30, 2025 | $4.15B | -72.6% | -66.4% | 36.67% |
| Mar 31, 2026 | $4.16B | -14.0% | +0.3% | 15.97% |
Revenue (annual, SEC 10-K)
2016: 0
2017: 0
2018: 0
2019: 18,348
2020: 18,486
2021: 18,450
2022: 19,140
2023: 19,440
2024: 20,175
2025: 17,146
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2016: 0
2017: 1,250
2018: 2,461
2019: 2,144
2020: 2,093
2021: 1,527
2022: 2,512
2023: 1,723
2024: 1,857
2025: 2,776
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 20Improving
80% conf
Latest annual report (10-K) filed Feb 12, 2026. Latest quarterly report (10-Q) filed Apr 28, 2026. 13 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 12, 2026.
- Latest quarterly report (10-Q) filed Apr 28, 2026.
- 13 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Kimberly-Clark Corp.; broad institutional reporting.
- Recent filers include INVESTORS TRUST CO /PA, INVESTORS TRUST CO /PA, INVESTORS TRUST CO /PA.
- 20 recent 13G passive institutional ownership notices.
Latest 10-K
Feb 12, 2026
Annual report
Latest 10-Q
Apr 28, 2026
8-K (recent)
13
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
0
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| INVESTORS TRUST CO /PA | 13F-HR | Feb 15, 2002 |
| INVESTORS TRUST CO /PA | 13F-HR | May 10, 2001 |
| INVESTORS TRUST CO /PA | 13F-HR | Oct 12, 2001 |
| INVESTORS TRUST CO /PA | 13F-HR | Jul 12, 2001 |
| Axiom Investment Management LLC | 13F-HR | Mar 16, 2021 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| May 14, 2026 | 8-K | 2026 ANNUAL MEETING RESULTS |
| May 5, 2026 | 8-K | 8-K |
| Apr 28, 2026 | 8-K | 8-K |
| Jan 29, 2026 | 8-K | FORM 8-K |
| Jan 27, 2026 | 8-K | 8-K |
| Jan 16, 2026 | 8-K | FORM 8-K |
| Dec 4, 2025 | 8-K | 8-K |
| Nov 7, 2025 | 8-K | 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -47Deteriorating
68% conf
3 risk signal(s), 2 positive signal(s), 2 watch item(s) detected from XBRL filing diff analysis. 3 risk signal(s) detected versus 2 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- NEW: Going concern doubt in latest filing: The term "going concern" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 1 filing(s).
- NEW: Material weakness in internal controls in latest filing: The term "material weakness" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 20 filing(s).
- NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 1 filing(s).
- Operating cash flow exceeds net income: OCF is 2.01x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Gross margin expansion: Gross margin expanded +5.7%pp (from 30.8% to 36.6%), indicating improved pricing power, cost efficiency, or favorable product mix.
- NEW: Impairment charge: Impairment charge appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: 3 risk signal(s) detected versus 2 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 5 new risk-language term(s) detected in filing text: Going concern doubt, Material weakness in internal controls, Restatement of financial statements, Impairment charge, Off-balance sheet arrangements.
Revenue
$17.15B
-15.0% YoY
Gross profit
$6.27B
+0.8% YoY
Operating income
$1.93B
-28.1% YoY
Net income
$1.76B
-8.8% YoY
Operating cash flow
$3.54B
+29.6% YoY
Capex
$766.0M
-12.6% YoY
Total assets
$16.55B
-4.6% YoY
Long-term debt
$6.70B
+8.5% YoY
Filing quality score
65/100
stable
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $20.18B | $17.15B | $-3.03B | -15.0% |
| Gross profit | $6.22B | $6.27B | $50.0M | +0.8% |
| Operating income | $2.68B | $1.93B | $-753.0M | -28.1% |
| Net income | $1.93B | $1.76B | $-170.0M | -8.8% |
| Operating cash flow | $2.73B | $3.54B | $809.0M | +29.6% |
| Capex | $876.0M | $766.0M | $-110.0M | -12.6% |
| Total assets | $17.34B | $16.55B | $-798.0M | -4.6% |
| Long-term debt | $6.18B | $6.70B | $525.0M | +8.5% |
| Cash & equivalents | $1.09B | $1.01B | $-83.0M | -7.6% |
| Stockholders equity | $915.0M | $840.0M | $-75.0M | -8.2% |
| Inventory | $1.96B | $1.45B | $-503.0M | -25.7% |
| Accounts receivable | $2.13B | $1.73B | $-407.0M | -19.1% |
| R&D expense | $292.0M | $303.0M | $11.0M | +3.8% |
| Interest expense | $282.0M | $293.0M | $11.0M | +3.9% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Removed | AccruedAdvertisingCurrent, AccruedSalariesCurrent, AdvertisingExpense, AllowanceForDoubtfulAccountsReceivableCurrent, AmortizationOfIntangibleAssets, AociLossCashFlowHedgeCumulativeGainLossAfterTax, AssetImpairmentCharges, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentIncomeTaxExpenseBenefit |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 1 | 0 | NEW |
| Material weakness in internal controls | high | 20 | 0 | NEW |
| Restatement of financial statements | high | 1 | 0 | NEW |
| Impairment charge | medium | 38 | 0 | NEW |
| Restructuring | medium | 79 | 4 | Ongoing |
| Off-balance sheet arrangements | medium | 5 | 0 | NEW |
Filing signal breakdown
Red flags: 3
Positive: 2
Watch: 2
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $38.08B at $114.72 per share.
- ProPrice & TechnicalsPrice $114.72 — uptrend (above 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Elevated.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite -10
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Kimberly-Clark Corp. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewMarket cap $38.08B at $114.72 per share..
Risk
Elevated
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow KMB stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Zoetis Inc. ZTS | 3 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Gilead Sciences GILD | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Moderna Inc. MRNA | -4 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| DexCom Inc. DXCM | -7 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Vertex Pharmaceuticals VRTX | -8 | Neutral |
| Kimberly-Clark Corp. KMB● you | -10 | Neutral |
| Sysco Corp. SYY | -10 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Biogen Inc. BIIB | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Thermo Fisher Scientific TMO | -18 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Hershey Co. HSY | -26 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |